Stabilization of hypoxia inducible factor-1α ameliorates acute renal neurogenic hypertension

Journal of Hypertension

Volumn 32, Issue 3, 2014, Pages 587-597

  Koeners, Maarten P ^a   Vink, Eva E ^a   Kuijper, Arno ^a   Gadellaa, Niels ^a   Rosenberger, Christian ^b   Mathia, Susanne ^b   Van Den Meiracker, Anton H ^c   Garrelds, Ingrid M ^c   Blankestijn, Peter J ^a   Joles, Jaap A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute neurogenic hypertension; Heme oxygenase 1; Hypoxia inducible factor 1 ; Kidney ischemia; Renal hemodynamics

Indexed keywords

COBALT CHLORIDE; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHENOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EFFERENT NERVE; GENE EXPRESSION REGULATION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSTRUMENTAL CONDITIONING; KIDNEY DENERVATION; KIDNEY ISCHEMIA; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RENAL NEUROGENIC HYPERTENSION; SYMPATHETIC TONE; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; COBALT; GENE EXPRESSION; HEME OXYGENASE (DECYCLIZING); HYPERTENSION, RENAL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; MALE; PHENOL; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 84894029763     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000060     Document Type: Article

References (38)

1. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
2. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22:208-215.
3. Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002; 39:1101-1106.
4. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002; 15:717-724.
5. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51:722-727.
6. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27:1341-1349.
7. Siddiqi L, Prakken NH, Velthuis BK, Cramer MJ, Oey PL, Boer P, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010; 25:3272-3277.
8. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17:1057-1062.
9. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433.
10. Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, et al. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am J Pathol 2007; 170:830-842.
11. Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 2007; 25:157-161.
12. Semenza GL. Hypoxia-inducible factor 1: master regulator of o2 homeostasis. Curr Opin Genet Dev 1998; 8:588-594.
13. Semenza GL. Hif-1, o(2), and the 3 phds: how animal cells signal hypoxia to the nucleus. Cell 2001; 107:1-3.
14. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the hif hydroxylase pathway. Mol Cell 2008; 30:393-402.
15. Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 2009; 11:56-62.
16. Abraham NG, Cao J, Sacerdoti D, Li X, Drummond G. Heme oxygenase: the key to renal function regulation. Am J Physiol Renal Physiol 2009; 297:F1137-1152.
17. Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 2004; 279:40337-40344.
18. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-5454.
19. Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schodel J, et al. Donor treatment with a phd-inhibitor activating hifs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc Natl Acad Sci U S A 2009; 106:21276-21281.
20. Wang Z, Schley G, Turkoglu G, Burzlaff N, Amann KU, Willam C, et al. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to epo treatment. Nephrol Dial Transplant 2012; 27:929-936.
21. Yang CC, Lin LC, Wu MS, Chien CT, Lai MK. Repetitive hypoxic preconditioning attenuates renal ischemia/reperfusion induced oxidative injury via upregulating hif-1 alpha-dependent bcl-2 signaling. Transplantation 2009; 88:1251-1260.
22. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11:723-728.
23. Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003; 14:1825-1832.
24. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, et al. Expression of hypoxia-inducible factor-1alpha and - 2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13:1721-1732.
25. Eickelberg O, Seebach F, Riordan M, Thulin G, Mann A, Reidy KH, et al. Functional activation of heat shock factor and hypoxia-inducible factor in the kidney. J Am Soc Nephrol 2002; 13:2094-2101.
26. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2:349-359.
27. Colgan SP, Eltzschig HK. Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery. Annu Rev Physiol 2012; 74:153-175.
28. Janssen BJ, van Essen H, Struyker Boudier HA, Smits JF. Hemodynamic effects of activation of renal and mesenteric sensory nerves in rats. Am J Physiol 1989; 257:R29-36.
29. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009; 24:1082-1088.
30. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 1995; 269:F838-845.
31. Vaziri ND, Wang ZQ. Sustained systemic arterial hypertension induced by extended hypobaric hypoxia. Kidney Int 1996; 49:1457-1463.
32. Tojo A, Doumoto M, Oka K, Numabe A, Kimura K, Yagi S. Endothelinmediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Physiol 1996; 270:R744-748.
33. Freeman RS, Barone MC. Targeting hypoxia-inducible factor (hif) as a therapeutic strategy for cns disorders. Curr Drug Targets CNS Neurol Disord 2005; 4:85-92.
34. Semenza GL, Prabhakar NR. Hif-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007; 9:1391-1396.
35. Li N, Chen L, Yi F, Xia M, Li PL. Salt-sensitive hypertension induced by decoy of transcription factor hypoxia-inducible factor-1alpha in the renal medulla. Circ Res 2008; 102:1101-1108.
36. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
37. Norman JT, Stidwill R, Singer M, Fine LG. Angiotensin ii blockade augments renal cortical microvascular po2 indicating a novel, potentially renoprotective action. Nephron Physiol 2003; 94:39-46.
38. Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15:1277-1288.